-
1 week ago | 
managedhealthcareexecutive.com | Logan Lutton
Patients taking nucleoside reverse transcriptase inhibitors (NRTIs) to treat their HIV have a decreased annual risk of developing Alzheimer’s disease by an average of 9% every year, according to research published today in Alzheimer’s and Dementia.
-
1 week ago | 
managedhealthcareexecutive.com | Logan Lutton
Vanda Pharmaceuticals Inc. announced that a New Drug Application for Bysanti (milsaperidone), for the treatment of acute bipolar I disorder and schizophrenia, has been accepted by the FDA, according to a news release published yesterday. A Prescription Drug User Fee Act (PDUFA) date for this application has been set for February 21, 2026. If approved, Bysanti could be available for sale in the United States in 2026.
-
1 week ago | 
managedhealthcareexecutive.com | Logan Lutton
Each Sunday we feature a highlight reel of various articles posted on our website that week. We’ll be back on Monday morning with more fresh content!
-
1 week ago | 
managedhealthcareexecutive.com | Logan Lutton
More children and young adults with chronic conditions such as depression and asthma experienced prescription disruptions in states with the biggest drops in Medicaid enrollment during the “unwinding process” when compared to states with smaller drops, according to a recent study done by the University of Michigan and published in Pediatrics. This study was conducted by a team at the University of Michigan’s Susan B.
-
1 week ago | 
managedhealthcareexecutive.com | Logan Lutton |Kennedy Ferruggia
The ongoing problem of brick-and-mortar pharmacy closures will not be exacerbated by the move to digital pharmacies, according to David Skomo, COO of HealthDyne. In fact, Skomo said he sees digital pharmacy as a solution. “There is a problem presented with a lack of easily accessible pharmacy care, as we see closures across our country,” Skomo said in an interview with Managed Healthcare Executive.
-
2 weeks ago | 
managedhealthcareexecutive.com | Logan Lutton
The FDA has approved Johnson and Johnson’s Imaavy (nipocalimab-aahu), the first and only FcRn blocker approved to treat adult and pediatric generalized myasthenia gravis (gMG) patients ages 12 and older in the United States, according to a news release. Myasthenia gravis (MG) is a chronic autoantibody disease in which the immune system produces antibodies (anti-acetylcholine receptor [AChR], anti-muscle-specific tyrosine kinase [MuSK]) that attack proteins at the neuromuscular junction.
-
2 weeks ago | 
managedhealthcareexecutive.com | Logan Lutton |Kennedy Ferruggia
Improving patient care access is just the tip of the iceberg when it comes to digital innovations in specialty pharmacy, according to David Skomo, COO of HealthDyne. “It's not just about telemedicine visits and telehealth visits with pharmacists,” Skomo said in an interview with Managed Healthcare Executive.
-
2 weeks ago | 
managedhealthcareexecutive.com | Logan Lutton |Kennedy Ferruggia |Briana Contreras
More GLP-1s and Oral Options Could Shift the Weight Loss Drug Market | Asembia's AXS25 SummitBecky Davis of Charles River Associates predicts that an influx of new and oral GLP-1 drugs, along with pricing pressures from policy and competition, will reshape the weight loss drug market in the next two years.
-
2 weeks ago | 
managedhealthcareexecutive.com | Logan Lutton
New research is shedding light on how physical abuse can impact the severity of menopause symptoms. A Turkish study published this month in Menopause has reported that 71% of postmenopausal women reported physical abuse from their partners and 62% of postmenopausal women reported verbal abuse. Additional forms of self-reported abuse and their frequency included psychological (29%), economic (4.3%) and sexual (1.4%).
-
2 weeks ago | 
managedhealthcareexecutive.com | Logan Lutton |Kennedy Ferruggia |Briana Contreras
Access to GLP-1s for Weight Loss Depends on Employer Choices | Asembia's AXS25 SummitAt the 2024 Asembia Specialty Pharmacy Summit, Becky Davis, principal at Charles River Associates, discussed how employer-based insurance coverage for GLP-1s remains uneven—and what factors are influencing decisions about access to these weight-loss treatments.
